Table 2.

Tumor characteristics of COVID-19 positive cancer patients.

	Total (n = 156)		WHO COVID grade
			Mild/moderate (n = 128)		Severe (n = 28)
	n	%	n	%	n	%
Cancer type
Urological/gynae	45	28.80	39	30.50	6	21.40
Gastro-intestinal	21	13.50	19	14.80	2	7.10
Hematological	28	17.90	18	14.10	10	35.70
Skin/head and neck/sarcoma	10	6.40	9	7.00	1	3.60
Central nervous system	11	7.10	10	7.80	1	3.60
Breast	24	15.40	21	16.40	3	10.70
Lung	17	10.90	12	9.40	5	17.90
Cancer stage
I	17	10.90	17	13.30	0	0.00
II	23	14.70	21	16.40	2	7.10
III	22	14.10	18	14.10	4	14.30
IV	63	40.40	49	38.30	14	50.00
Missing	31	19.90	23	18.00	8	28.60
Risk category* (n = 4)
Low	1	25.00	0	0.00	1	33.33
Intermediate	2	50.00	1	100.00	1	33.33
High	1	25.00	0	0.00	1	33.33
Treatment paradigm
Treatment naive	18	11.50	16	12.50	2	7.10
Neoadjuvant	7	4.50	7	5.50	0	0.00
Adjuvant	8	5.10	8	6.30	0	0.00
Radical	38	24.40	28	21.90	10	35.70
Palliative	60	38.50	49	38.30	11	39.30
Watch and wait	7	4.50	7	5.50	0	0.00
Surveillance	12	7.70	10	7.80	2	7.10
Missing	6	3.80	3	2.30	3	10.70
Line of palliative treatment (N = 54)
1	27	50.00	23	52.27	4	40.00
2	18	33.33	13	29.55	5	50.00
3	6	11.11	5	11.36	1	10.00
4	1	1.90	1	2.27	0	0.00
Missing	2	3.70	2	4.55	0	0.00
Systemic treatment (N = 81)
Systemic chemotherapy	45	55.60	34	53.10	11	64.60
Immunotherapy	7	8.60	5	7.80	2	11.80
Biological	13	16.00	11	17.20	2	11.80
Targeted therapy	5	6.20	5	7.80	0	0.00
Combination therapy	11	13.60	9	14.10	2	11.80
Time since cancer diagnosis
<3 months	41	26.30	34	26.60	7	25.00
3–12 months	30	19.20	25	19.50	5	17.90
12–24 months	20	12.80	18	14.10	2	7.10
>24 months	57	36.50	45	35.20	12	42.90
Performance status
0	19	12.20	17	13.30	2	7.10
1	43	27.60	34	26.60	9	32.10
2	33	21.20	27	21.10	6	21.40
3	14	9.00	13	10.20	1	3.60
4	6	3.80	5	3.90	1	3.60

^*For myeloid malignancies only.